ROCHE’S monoclonal antibody
gantenerumab has been found to
remove amyloid plaques from the
brain of patients with Alzheimer’s
disease.
The Phase I trial finding,
published in Archives of Neurology,
marks the first time that clinical
data has been published for
gantenerumab, an investigational
fully human anti-amyloid beta
monoclonal antibody which is
designed to bind to amyloid
plaques in the brain and remove
them.
“These results and especially the
rapidity of the effects observed on
amyloid removal are very
encouraging and pave the way for
the development of a novel
treatment for Alzheimer’s disease,”
said Luca Santarelli, Global Head of
Roche Neuroscience Disease
Translational Area.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Oct 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Oct 11
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.